Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Colorcon
Moodys
Harvard Business School
Johnson and Johnson
Dow

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 7,273,718

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,273,718
Title:Isolated genomic polynucleotide fragments from chromosome 10q25.3 that encode human soluble aminopeptidase P
Abstract: The invention is directed to an isolated genomic polynucleotide fragment that encodes human soluble (cytosolic) aminopeptidase P, vectors and hosts containing the fragment and fragments hybridizing to noncoding regions as well as antisense oligonucleotides to these fragments. The invention is further directed to methods of using these fragments to obtain human soluble aminopeptidase P and to diagnose, treat, prevent and/or ameliorate a pathological disorder.
Inventor(s): Ryan; James W. (Augusta, GA)
Assignee: Ryogen LLC (Suffern, NY)
Application Number:10/457,715
Patent Claims:1. An isolated genomic polynucleotide, wherein said polynucleotide can be isolated from human chromosome 10 and is selected from the group consisting of: (a) a polynucleotide consisting of the nucleic acid sequence set forth in SEQ ID NO:2, (b) a polynucleotide consisting of the sequence of nucleotides from position 12803 to position 55760 of SEQ ID NO:2, and (c) a polynucleotide which is the complement of a polynucleotide of (a) or (b) and encodes a polypeptide having aminoacyl prolyl peptidyl hydrolase activity.

2. A composition comprising the polynucleotide of claim 1 and a carrier.

3. An expression vector comprising a polynucleotide consisting of the sequence of nucleotides from position 12803 to position 55760 of SEQ ID NO:2 or the complement thereof in operable linkage with a heterologous promoter.

4. A recombinant host cell comprising the expression vector of claim 3.

5. A method for obtaining a polypeptide having aminoacyl prolyl peptidyl hydrolase activity comprising (a) culturing the recombinant host cell of claim 4 under conditions that provide for the expression of said polypeptide, and (b) recovering said expressed polypeptide.

6. A method of identifying a nucleotide sequence variant of SEQ ID NO:2 or its complementary sequence comprising (a) isolating genomic DNA from a subject, and (b) determining the presence or absence of a nucleotide sequence variation in said genomic DNA by comparing the nucleotide sequence of SEQ ID NO:2 with the nucleotide sequence of the isolated genomic DNA and establishing if and where a difference occurs between the two nucleotide sequences thereby identifying a nucleotide sequence variant of SEQ ID NO:2.

7. The method according to claim 6, wherein the presence or absence of a nucleotide sequence variation is determined in a 5'-noncoding region, 3'-noncoding region or intron region of SEQ ID NO:2 or its complementary sequence.

8. An isolated polynucleotide consisting of a nucleic acid sequence selected from the group consisting of (a) a sequence of at least 5000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 1 through position 12802 of SEQ ID NO:2, (b) a sequence of at least 2000 contiguous nucleotides within the region consisting of the sequence of nucleotides from position 55761 through position 58735 of SEQ ID NO:2, (c) a sequence of nucleotides complementary to the nucleotide sequence of (a), and (d) a sequence of nucleotides complementary to the nucleotide sequence of (b).

9. A composition comprising the polynucleotide of claim 8 and a carrier.

10. A kit comprising one or more polynucleotides of claim 8, optionally labeled.

11. The kit according to claim 10, wherein which further comprises the polynucleotide of clause (b) of claim 1or its complementary sequence, optionally labelled.

12. A solid support comprising one or more polynucleotides of claim 8.

13. The solid support of claim 12 wherein said support is a microarray.

14. The solid support of claim 12, wherein said solid support is a microarray, and wherein the microarray further comprises a polynucleotide of claim 1.

15. A method of detecting the presence or absence of a polynucleotide having the nucleic acid sequence set forth in SEQ ID NO:2 or its complementary sequence in a sample, said method comprising (a) contacting the sample with a polynucleotide of claim 8 in 50% formamide and 5.times.SCC at 65.degree. C., and (b) determining whether the polynucleotide binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to a polynucleotide of claim 6 detects the presence of a polynucleotide comprising SEQ ID NO:2.

16. An isolated polynucleotide consisting of a fragment of the polynucleotide of claim 1, said fragment consisting of an intron region of SEQ ID NO:2 selected from the group consisting of the sequence of nucleotides, between positions 18525 19411, the sequence of nucleotides between positions 19481 20985, the sequence of nucleotides between positions 21046 23146, the sequence of nucleotides between positions 23219 25408, the sequence of nucleotides between positions 25679 28128, the sequence of nucleotides between positions 28873 30372, the sequence of nucleotides between positions 32088 34184, the sequence of nucleotides between positions 34284 36002, the sequence of nucleotides between positions 36550 39674, and the sequence of nucleotides between positions 41031 55646 of SEQ ID NO:2 and nucleic acid sequence regions that are the complements thereof.

17. A composition comprising the polynucleotide of claim 16 and a carrier.

18. A kit comprising one or more polynucleotides of claim 16, optionally labeled.

19. A solid support comprising one or more polynucleotides of claim 16.

20. The solid support of claim 19 wherein said support is a microarray.

21. A method of detecting the presence or absence of a polynucleotide having the nucleic acid sequence set forth in SEQ ID NO:2 or its complementary sequence in a sample, said method comprising (a) contacting the sample with a polynucleotide of claim 15 in 50% formamide and 5.times.SCC at 65.degree. C., and (b) determining whether the polynucleotide binds to a polynucleotide sequence in the sample, wherein binding of a polynucleotide of the sample to a polynucleotide of claim 16 detects the presence of a polynucleotide comprising SEQ ID NO:2.

Details for Patent 7,273,718

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2022-06-07
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2022-06-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Dow
Baxter
Harvard Business School
Mallinckrodt
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.